Introduction The presence of ROS proto-oncogene 1, receptor tyrosine kinase gene (ROS1)
rearrangements in lung cancers confers sensitivity to ROS kinase inhibitors, including …

ROS1 gene rearrangements are reported in 1% to 2% of lung adenocarcinomas (ACAs) and
are associated with response to the multitargeted tyrosine kinase inhibitor crizotinib. ROS1 …

ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor,
crizotinib. We investigated the usefulness of ROS1 immunohistochemistry (IHC) for the …

Aims To compare fluorescence in situ hybridization (FISH), immunohistochemistry (IHC) and
quantitative real-time reverse transcription-PCR (qRT-PCR) assays for detection of ROS1 …

Patients with non-small cell lung cancer (NSCLC) harboring ROS proto-oncogene 1 (ROS1)
gene rearrangements show dramatic response to the tyrosine kinase inhibitor (TKI) …

Purpose Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase gene
have recently been described in a subset of non–small-cell lung cancers (NSCLCs) …

ROS proto-oncogene 1 (ROS1) rearrangements are reported in about 1–2% of non-
squamous non-small-cell lung cancer (NSCLC). After efficacy of crizotinib was …

Rearrangements of the ROS1 gene occur in 1–2% of non-small cell lung cancers (NSCLCs).
Crizotinib, a highly effective inhibitor of ROS1 kinase activity, is now FDA-approved for the …

Introduction The detection of a ROS1 rearrangement in advanced and metastatic lung
adenocarcinoma (LUAD) led to a targeted treatment with tyrosine kinase inhibitors with …

Purpose: Oncogenic gene fusions involving the 3′ region of ROS1 kinase have been
identified in various human cancers. In this study, we sought to characterize ROS1 fusion …